life scienc tool diagnost
labcorp america lh
ep exce consensu lh ep beat
weaker revenu off-set better profit factor line
neg impact ep lh rais ep guidanc
vs consensu rais ep
reflect beat tp move
ebitda higher view
slightli reflect contract shift
divestitur bp fx bp one less sale day quarter
underli organ growth lcd declin vs estimate
expect rose organ basi despit pama
headwind bp organ volum rise sequenti
improv weather bump off-set contract
shift revenu per access compar favor
covanc larg line organ encouragingli
post ttm btb vs estimate ebit margin declin
bp acquisit mix pama reserv stand million
flow million help fund share repurchas million
reiter outperform lh share grind higher sequenti
improv organ volum trend across core lab segment respect
cro book strength testament diversif effort
hearten recent envigo deal rais ep guid
fulli reflect beat vs con despit envigo
expect accret would expect element conservat
transit year multipl variabl particularli amid contract move
focu call greater detail contract roll off/pama
reflect guid quarterli cro btb prospect lead lab
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
labcorp provid diagnost test inform servic
labcorp america lh
price apr rate outperform target price analyst erin wright
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
better fundament perform sentiment could drive upsid
target price blue sky scenario lh
weaker fundament perform sentiment could lead
downsid versu target price grey sky scenario
lh
labcorp america lh
compani mention price
labcorp america lh outperform tp
